Logo
N

NeuroActiva, Inc.

15 employees

Dedicated to the discovery, development, and commercialization of new drugs to treat and prevent Alzheimer’s disease and Covid-19

Basic info

Industry

biotechnology research

Sectors

Biotechnology
amyotrophic lateral sclerosis
Alzheimer drug developer
Parkinson's disease
regulatory affairs
neuroprotection
NA-901
NA-704
clinical trials
New drug discovery
NA-831
FDA affairs
neurogenesis
Biopharmaceutical
Alzheimer's disease
MICROS
Biopharmaceutical drug developer
ALS
pharmaceutical company
Multiple sclerosis
Membrane controlled release optimization system
Traneurocin
Micros Infuser
Vineurocin

FAQ